Patent application number | Description | Published |
20080280972 | Iminosugar treatment of tumors - A proliferation of cells can be reduced by contacting the cells with a compound having formula (I) | 11-13-2008 |
20090252785 | ENDOPLASMIC RETICULUM TARGETING LIPOSOMES - Provided are compositions that include lipid particles, such as liposomes, that can fuse with the ER membrane of a cell. The lipid particles can also deliver a cargo, such as a therapeutic or an imaging agent, encapsulated inside the particles inside the ER lumen of the cell. The compositions can be useful for treating and/or preventing diseases or conditions caused by or associated with a virus, such as viral infections, including HIV and HCV infections. | 10-08-2009 |
20100137365 | Long chain N-alkyl compounds and oxa-derivatives thereof - Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C | 06-03-2010 |
20100222383 | Iminosugars and methods of treating viral diseases - Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars. | 09-02-2010 |
20100222384 | Iminosugars and methods of treating arenaviral infections - Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Arenaviridae family using iminosugars, such as DNJ derivatives. | 09-02-2010 |
20100266678 | CHOLESTEROL LEVEL LOWERING LIPOSOMES - Provided are methods of reducing cellular cholesterol levels using lipid particles that are capable of cellular entry. Such lipid particles may be used for treating or preventing a disease or condition that is caused by or associated with an increased cellular cholesterol level and for treating or preventing a disease or condition, that is caused by or associated with a virus, that relies on cellular cholesterol for its replication. | 10-21-2010 |
20100291602 | CLINICAL DIAGNOSIS OF HEPATIC FIBROSIS USING A NOVEL PANEL OF LOW ABUNDANT HUMAN PLASMA PROTEIN BIOMARKERS - The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analysed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta/delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-III, apolipoprotein E, C4b-binding protein beta chain, intact/cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, hemopexin, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase/arylesterase 1, sex hormone-binding globulin and zinc-alpha-2-glycoprotein. These biomarkers can be used in conjunction with polypeptides in WO/2008/031051. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers. | 11-18-2010 |
20100317696 | IMINOSUGARS AND METHODS OF TREATING BUNYAVIRAL AND TOGAVIRAL DISEASES - Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Bunyaviridae or Togaviridae family using iminosugars, such as DNJ derivatives. | 12-16-2010 |
20110065752 | METHODS OF TREATING ORTHOMYXOVIRAL INFECTIONS - Provided are novel iminosugars and methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Orthomyxoviridae family using iminosugars, such as DNJ derivatives. | 03-17-2011 |
20110065753 | METHODS OF TREATING POXVIRAL INFECTIONS - Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Poxyiridae family using iminosugars, such as DNJ derivatives. | 03-17-2011 |
20110065754 | IMINOSUGARS AND METHODS OF TREATING FILOVIRAL DISEASES - Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Filoviridae family using iminosugars, such as DNJ derivatives. | 03-17-2011 |
20110182982 | LIPOSOME TREATMENT OF VIRAL INFECTIONS - One can treat a viral infection such as hepatitis B (HBV), hepatitis C(HCV), and bovine viral diarrhea virus (BVDV) infections via the delivery of pH sensitive liposomes directly into the endoplasmic reticulum (ER) membrane. Two exemplary liposome formulations are DOPE/CHEMS (DC liposomes) and DOPE/CHEMS/PEG-PE (DCPP liposomes). DC and DCPP liposomes can optimize the intracellular delivery of N-butyl deoxynojirimycin (NB-DNJ), and consequently increase the in vivo activity of this iminosugar several orders of magnitude, and could be used in combination with other therapeutic agents such as interferon and/or ribavirin. The optimized release of NB-DNJ directly into the ER can be also applied for the treatment of other viruses, for which NB-DNJ is known to be an effective antiviral, such as human immunodeficiency virus (HIV). | 07-28-2011 |
20110184019 | Long chain N-Alkyl compounds and oxa-derivatives thereof - Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C | 07-28-2011 |
20120237592 | ENDOPLASMIC RETICULUM TARGETING LIPOSOMES - Provided are compositions that include lipid particles, such as liposomes, that can fuse with the ER membrane of a cell. The lipid particles can also deliver a cargo, such as a therapeutic or an imaging agent, encapsulated inside the particles inside the ER lumen of the cell. The compositions can be useful for treating and/or preventing diseases or conditions caused by or associated with a virus, such as viral infections, including HIV and HCV infections. | 09-20-2012 |
20130150405 | IMINOSUGARS AND METHODS OF TREATING TOGAVIRAL DISEASES - Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Togaviridae family using iminosugars, such as DNJ derivatives. | 06-13-2013 |
20130237567 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES - Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars. | 09-12-2013 |